Digitonin

Digitonin is a steroidal saponin compound derived from foxglove plants that demonstrates anti-cancer properties through cell membrane permeabilization and apoptosis induction. Research shows it may inhibit gastric cancer cell proliferation with IC50 values of 1-5 μM in multiple cancer cell lines.

Origin & History

Digitonin is a steroidal saponin glycoside extracted primarily from the seeds and roots of Digitalis purpurea (foxglove) and Digitalis lanata (Grecian foxglove), plants native to Europe. It is obtained through solvent extraction using ethanol or water, followed by purification via chromatography or crystallization, featuring a spirostanol aglycone (digitogenin) linked to a tetrasaccharide chain.

Historical & Cultural Context

Digitonin has no documented historical use in traditional medicine systems as a distinct compound. While Digitalis species were used in 18th-century European folk medicine for heart conditions due to cardiac glycosides, digitonin was isolated later in the 19th century specifically for laboratory use, not therapeutic applications.

Health Benefits

• May inhibit gastric cancer cell proliferation - Preclinical evidence shows IC50 ~1-5 μM in MKN1, NUGC3, and HGC27 cell lines (PMID: 40206492)
• Could reduce tumor growth - Mouse xenograft models demonstrated tumor volume reduction comparable to 5-FU when administered intraperitoneally (PMID: 40206492)
• Potential to block cancer cell migration and invasion - In vitro studies using wound healing and transwell assays showed significant inhibition at 0.3125-20 μM (PMID: 40206492)
• May target HSP90AA1 and NFKB1 pathways - Network pharmacology and Western blot analysis confirmed downregulation of these cancer-related proteins (PMID: 40206492)
• Shows minimal toxicity to normal cells - GES-1 normal gastric cells showed low cytotoxicity at concentrations <1 μM (PMID: 40206492)

How It Works

Digitonin functions as a membrane-permeabilizing agent that selectively disrupts cholesterol-rich cell membranes, leading to cytotoxicity in cancer cells. It induces apoptosis through mitochondrial membrane permeabilization and activation of caspase pathways. The compound's selective toxicity toward cancer cells appears related to altered cholesterol metabolism in malignant tissues.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on digitonin as a therapeutic agent. A 2025 network pharmacology and experimental validation study (PMID: 40206492) evaluated digitonin in vitro using gastric cancer cell lines and in vivo using BALB/c nude mouse xenograft models with 5×10⁶ MKN1 cells per mouse (n=6-8 per group).

Clinical Summary

Current evidence for digitonin is limited to preclinical studies with no human clinical trials available. In vitro studies demonstrate anti-proliferative effects against gastric cancer cell lines (MKN1, NUGC3, HGC27) with IC50 values ranging from 1-5 μM. Mouse xenograft models showed tumor volume reduction comparable to 5-FU chemotherapy when administered intraperitoneally. The evidence remains preliminary and requires human studies to establish therapeutic potential and safety profiles.

Nutritional Profile

Digitonin is not a nutrient or food component; it is a steroidal saponin glycoside (C₅₆H₉₂O₂₉, molecular weight ~1229.3 g/mol) derived primarily from the seeds of Digitalis purpurea (purple foxglove). It consists of a spirostanol agenin (digitogenin) linked to a branched pentasaccharide chain composed of 2 glucose, 2 galactose, and 1 xylose unit. It has no macronutrient value (no protein, fat, carbohydrate, or fiber contribution to diet) and contains no vitamins or minerals. Its primary bioactive property is its ability to complex with membrane cholesterol (binding ratio ~1:1 molar with 3β-hydroxysterols), which underlies both its detergent-like membrane-permeabilizing activity and its pharmacological effects. Digitonin has very low oral bioavailability due to its large molecular size, high hydrophilicity of the sugar moiety, and susceptibility to gastrointestinal degradation; most preclinical anticancer studies utilize intraperitoneal or direct in vitro administration. Critical micelle concentration (CMC) is approximately 0.5 mM (~0.06% w/v) in aqueous solution. At sub-CMC concentrations (~1–5 μM, as used in cancer cell studies), it acts on cholesterol-rich membrane microdomains rather than as a bulk detergent. It is classified as toxic at higher doses (LD₅₀ in mice: ~5.7 mg/kg IV), and it is not approved for human dietary or therapeutic oral consumption. It is used exclusively as a research reagent (membrane permeabilization, cholesterol quantification assays) and as an investigational preclinical compound. No recommended dietary intake, tolerable upper limit, or nutritional reference value exists.

Preparation & Dosage

No clinically studied dosages exist due to lack of human trials. Preclinical in vitro studies used 0.3125-20 μM digitonin for 24-72 hours. In vivo mouse studies used intraperitoneal injections every 2 days for 4 weeks (approximately 10 mg/kg inferred from similar saponin models). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

5-Fluorouracil (5-FU), HSP90 inhibitors, PI3K inhibitors, HIF-1α inhibitors, NF-κB inhibitors

Safety & Interactions

Digitonin is highly cytotoxic and can cause severe membrane damage at higher concentrations, making it unsuitable for oral supplementation. No human safety data exists, and the compound may interact dangerously with cardiac medications due to its structural similarity to cardiac glycosides. Pregnancy and breastfeeding safety is unknown, and the compound should be avoided outside of research settings. Potential for serious adverse effects including hemolysis and cellular toxicity exists at therapeutic doses.